" /> Myoclonic epilepsy of lafora - CISMeF





Preferred Label : Myoclonic epilepsy of lafora;

CISMeF acronym : EPM2A; EPM2B; EPM2; LBD; MELF;

Type : Phenotype, molecular basis known;

Alternative titles and symbols : Lafora disease; Lafora body disease; Epilepsy, progressive myoclonic, 2a; MELF; LBD; EPM2A; EPM2;

Included titles and symbols : Epilepsy, progressive myoclonic, 2b; EPM2B;

Description : The Lafora type of progressive myoclonic epilepsy is an autosomal recessive disorder characterized by insidious onset of progressive neurodegeneration between 8 and 18 years of age. Initial features can include headache, difficulties in school work, myoclonic jerks, generalized seizures, and often visual hallucination. The myoclonus, seizures, and hallucinations gradually worsen and become intractable. This is accompanied by progressive cognitive decline, resulting in dementia. About 10 years after onset, affected individuals are in near-continuous myoclonus with absence seizures, frequent generalized seizures, and profound dementia or a vegetative state. Histologic studies of multiple tissues, including brain, muscle, liver, and heart show intracellular Lafora bodies, which are dense accumulations of malformed and insoluble glycogen molecules, termed polyglucosans (review by Ramachandran et al., 2009). For a discussion of genetic heterogeneity of progressive myoclonic epilepsy, see EPM1A (254800).;

Inheritance : Autosomal recessive;

Molecular basis : Caused by mutation in the malin gene (NHLRC1, 608072.0001); Caused by mutation in the laforin gene (EPM2A, 607566.0001);

Laboratory abnormalities : Intracellular PAS-positive polyglucosan inclusion bodies ('Lafora' bodies) can be found in various tissues (brain, liver, muscle, heart, skin);

Prefixed ID : #254780;

Details


You can consult :


Nous contacter.
02/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.